Consensus statement of the European Atherosclerosis Society on the 2022 lipoprotein(a) – responses to the frequently asked questions about these recommendations
Authors:
Lukáš Zlatohlávek; Vladimír Bláha; Renata Cífková; Tomáš Freiberger; David Karásek; Pavel Kraml; Jan Piťha; Hana Rosolová; Vladimír Soška; Tomáš Štulc; Michal Vrablík Za Výbor Čsat; Jana Mašková
Authors‘ workplace:
Česká společnost pro aterosklerózu
Published in:
AtheroRev 2024; 9(1): 7-17
Category:
Guidelines
Overview
The Committee of the Czech Society for Atherosclerosis (CSAT) has selected the most important information from the article by F. Kronenberg et al (Atherosclerosis 2023; 374), by which the authors responded to questions posed by the professional community on the EAS Consensus on lipoprotein(a) published in 2022 (Eur Heart J 2022; 43). The authors formulated the 30 most frequently asked questions, answered them briefly, and added explanatory commentary to the answers. From these comments, the CSAT Committee selected the most relevant information for the Czech environment.
Keywords:
aspirin – AtheroSclerotic CardioVascular Disease (ASCVD) – genetic factors Lp(a) – lipoprotein(a)/Lp(a) – Lp(a) concentration units – statins
Sources
Číselná označení citované literatury [1–136] odkazují na citace v originální verzi komentovaného článku, který je dostupný v online verzi:
Kronenberg F, Mora S, Stroes ESG et al. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis 2023; 374: 107–120. Dostupné z DOI: <https://doi: 10.1016/j.atherosclerosis.2023.04.012>.
Vrablík M, Blaha V, Cífková R et al. Stanovisko ČSAT ke Konsenzu Evropské společnosti pro aterosklerózu: Lipoprotein(a) při aterosklerotických kardiovaskulárních onemocněních a aortální stenóze. AtheroRev 2023; 8(2): 66–76.
Originální text doporučení EAS:
1. Kronenberg F, Mora S, Stroes ESG et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. Eur Heart J 2022; 43(39): 3925–3946. Dostupné z DOI: <https://doi.org/10.1093/eurheartj/ehac361>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2024 Issue 1
Most read in this issue
- I am 55 years old, my cholesterol is 6.5 mmol/l and I do not want statin
- Semaglutide confirms its position in cardiovascular prevention in the SELECT study
- Consensus statement of the European Atherosclerosis Society on the 2022 lipoprotein(a) – responses to the frequently asked questions about these recommendations
- First clinical experience with inclisiran in Slovakia – experience with administration, management and efficacy from one center